Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(TSX:MSCL)

15.74 +0.39 (+2.54%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MSCL

< Previous 1 2 Next >
News headline image
Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters’ Option to Purchase Additional Shares
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Announces Launch of Public Offering in Canada and the United States and Filing of Application to List on Nasdaq
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Announces Share Consolidation in Connection with Proposed Nasdaq Listing
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Receives Clearance by U.S. FDA and Global Regulators to Initiate Pediatric Phase 2 Study of SAT-3247 for Duchenne Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos to Participate in December Investor Conferences
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Announces Publication in Nature Communications Supporting its Novel Treatment Approach for Duchenne Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Reports Third Quarter 2025 Results and Announces Appointment of Mark Nawacki to Board of Directors
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos to Participate in November Investor Conferences
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Announces First Adult Patient Dosed in LT-001, an Open-Label, Long-Term Follow-Up Study of SAT-3247 in Duchenne Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Announces New Data Further Demonstrating Safety, Tolerability, and Functional Impact of SAT-3247 in First-in-Human Trial of Adults with Duchenne Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos to Present SAT-3247 Phase 1 Clinical Data in Late-Breaking Poster Session at the 2025 World Muscle Society Congress
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Announces IND Submission to the U.S. FDA and Global Regulatory Filings to Advance a Phase 2 Clinical Trial of SAT-3247 in Children with Duchenne Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos to Participate in Four September Institutional and Retail Investor Conferences
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Reports Second Quarter 2025 Results and Highlights Upcoming Clinical Milestones
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos to Present at Canaccord Genuity’s 45th Annual Growth Conference
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Bioscience Shareholders Elect Two New Board Members
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Bioscience Announces Results of Annual and Special Meeting of Shareholders
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Bioscience to Participate in PPMD’s Annual Conference in Las Vegas
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Announces Encouraging Functional Data from the 28-day Phase 1b Open-Label Trial of SAT-3247 in Adults with Duchenne Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Reports First Quarter 2025 Results and Highlights Recent Company Progress
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos to Present at the CureDuchenne FUTURES National Conference
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos to Present at Bloom Burton & Co. Healthcare Investor Conference
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos to Participate in Two April Investor Conferences
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Reports 2024 Financial Results and Highlights Company Progress
From Satellos Bioscience Inc.
Via Business Wire
News headline image
Satellos Presents Initial Data from the Phase 1 Trial of SAT-3247 at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
From Satellos Bioscience Inc.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.